1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Pfizer Pulls Plug But iTeos Has High Hopes For IDO1 Inhibitor

 
• By Kevin Grogan

The Belgian biotech has regained the rights to an early-stage IDO1 inhibitor that has failed a Phase I trial but iTeos believes the drug's penetration to the brain makes EOS200271 a significant asset.

Doors
Door closes, another opens: iTeos upbeat despite Pfizer pact ending • Source: Shutterstock

News that Pfizer Inc. is returning the rights to its indoleamine 2,3-dioxygenase (IDO1) inhibitor is a surprise but represents an opportunity for iTeos Therapeutics SA, according to the Belgian biotech's CEO Michel Detheux.

It has been confirmed this morning (Jan. 4) that the US behemoth has handed back worldwide rights to EOS200271, an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer